Cargando…
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
The wide transmission and host adaptation of SARS-CoV-2 have led to the rapid accumulation of mutations, posing significant challenges to the effectiveness of vaccines and therapeutic antibodies. Although several neutralizing antibodies were authorized for emergency clinical use, convalescent patien...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828845/ https://www.ncbi.nlm.nih.gov/pubmed/35140196 http://dx.doi.org/10.1038/s41392-022-00912-4 |
_version_ | 1784647930207010816 |
---|---|
author | Chi, Xiaojing Zhang, Xinhui Pan, Shengnan Yu, Yanying Shi, Yujin Lin, Tianli Duan, Huarui Liu, Xiuying Chen, Wenfang Yang, Xuehua Chen, Lan Dong, Xiaoqian Ren, Lili Ding, Qiang Wang, Jianwei Yang, Wei |
author_facet | Chi, Xiaojing Zhang, Xinhui Pan, Shengnan Yu, Yanying Shi, Yujin Lin, Tianli Duan, Huarui Liu, Xiuying Chen, Wenfang Yang, Xuehua Chen, Lan Dong, Xiaoqian Ren, Lili Ding, Qiang Wang, Jianwei Yang, Wei |
author_sort | Chi, Xiaojing |
collection | PubMed |
description | The wide transmission and host adaptation of SARS-CoV-2 have led to the rapid accumulation of mutations, posing significant challenges to the effectiveness of vaccines and therapeutic antibodies. Although several neutralizing antibodies were authorized for emergency clinical use, convalescent patients derived natural antibodies are vulnerable to SARS-CoV-2 Spike mutation. Here, we describe the screen of a panel of SARS-CoV-2 receptor-binding domain (RBD) targeted nanobodies (Nbs) from a synthetic library and the design of a biparatopic Nb, named Nb1–Nb2, with tight affinity and super-wide neutralization breadth against multiple SARS-CoV-2 variants of concern. Deep-mutational scanning experiments identify the potential binding epitopes of the Nbs on the RBD and demonstrate that biparatopic Nb1–Nb2 has a strong escape-resistant feature against more than 60 tested RBD amino acid substitutions. Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621). Furthermore, a heavy-chain antibody is constructed by fusing the human IgG1 Fc to Nb1–Nb2 (designated as Nb1–Nb2-Fc) to improve its neutralization potency, yield, stability, and potential half-life extension. For the new Omicron variant (B.1.1.529) that harbors unprecedented multiple RBD mutations, Nb1–Nb2-Fc keeps a firm affinity (KD < 1.0 × 10(−12) M) and strong neutralizing activity (IC(50) = 1.46 nM for authentic Omicron virus). Together, we developed a tetravalent biparatopic human heavy-chain antibody with ultrapotent and broad-spectrum SARS-CoV-2 neutralization activity which highlights the potential clinical applications. |
format | Online Article Text |
id | pubmed-8828845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88288452022-02-24 An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants Chi, Xiaojing Zhang, Xinhui Pan, Shengnan Yu, Yanying Shi, Yujin Lin, Tianli Duan, Huarui Liu, Xiuying Chen, Wenfang Yang, Xuehua Chen, Lan Dong, Xiaoqian Ren, Lili Ding, Qiang Wang, Jianwei Yang, Wei Signal Transduct Target Ther Article The wide transmission and host adaptation of SARS-CoV-2 have led to the rapid accumulation of mutations, posing significant challenges to the effectiveness of vaccines and therapeutic antibodies. Although several neutralizing antibodies were authorized for emergency clinical use, convalescent patients derived natural antibodies are vulnerable to SARS-CoV-2 Spike mutation. Here, we describe the screen of a panel of SARS-CoV-2 receptor-binding domain (RBD) targeted nanobodies (Nbs) from a synthetic library and the design of a biparatopic Nb, named Nb1–Nb2, with tight affinity and super-wide neutralization breadth against multiple SARS-CoV-2 variants of concern. Deep-mutational scanning experiments identify the potential binding epitopes of the Nbs on the RBD and demonstrate that biparatopic Nb1–Nb2 has a strong escape-resistant feature against more than 60 tested RBD amino acid substitutions. Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621). Furthermore, a heavy-chain antibody is constructed by fusing the human IgG1 Fc to Nb1–Nb2 (designated as Nb1–Nb2-Fc) to improve its neutralization potency, yield, stability, and potential half-life extension. For the new Omicron variant (B.1.1.529) that harbors unprecedented multiple RBD mutations, Nb1–Nb2-Fc keeps a firm affinity (KD < 1.0 × 10(−12) M) and strong neutralizing activity (IC(50) = 1.46 nM for authentic Omicron virus). Together, we developed a tetravalent biparatopic human heavy-chain antibody with ultrapotent and broad-spectrum SARS-CoV-2 neutralization activity which highlights the potential clinical applications. Nature Publishing Group UK 2022-02-09 /pmc/articles/PMC8828845/ /pubmed/35140196 http://dx.doi.org/10.1038/s41392-022-00912-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chi, Xiaojing Zhang, Xinhui Pan, Shengnan Yu, Yanying Shi, Yujin Lin, Tianli Duan, Huarui Liu, Xiuying Chen, Wenfang Yang, Xuehua Chen, Lan Dong, Xiaoqian Ren, Lili Ding, Qiang Wang, Jianwei Yang, Wei An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants |
title | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants |
title_full | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants |
title_fullStr | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants |
title_full_unstemmed | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants |
title_short | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants |
title_sort | ultrapotent rbd-targeted biparatopic nanobody neutralizes broad sars-cov-2 variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828845/ https://www.ncbi.nlm.nih.gov/pubmed/35140196 http://dx.doi.org/10.1038/s41392-022-00912-4 |
work_keys_str_mv | AT chixiaojing anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT zhangxinhui anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT panshengnan anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT yuyanying anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT shiyujin anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT lintianli anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT duanhuarui anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT liuxiuying anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT chenwenfang anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT yangxuehua anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT chenlan anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT dongxiaoqian anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT renlili anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT dingqiang anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT wangjianwei anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT yangwei anultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT chixiaojing ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT zhangxinhui ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT panshengnan ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT yuyanying ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT shiyujin ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT lintianli ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT duanhuarui ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT liuxiuying ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT chenwenfang ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT yangxuehua ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT chenlan ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT dongxiaoqian ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT renlili ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT dingqiang ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT wangjianwei ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants AT yangwei ultrapotentrbdtargetedbiparatopicnanobodyneutralizesbroadsarscov2variants |